Abstract
Experimental and clinical data suggest that stents eluting antiproliferative agents can be used for the prevention of in-stent restenosis. Here we investigate in vitro the antiproliferative and apoptotic effect of D-24851 and evaluate the safety and efficacy of D-24851-eluting polymer-coated stents in a rabbit restenosis model (n = 53). Uncoated stents (n = 6), poly (dl-lactide-co-glycolide) (PLGA)-coated stents (n = 7), and PLGA-coated stents loaded with 0.08 ± 0.0025 μM (31 ± 1 μg; low dose; n = 7), 0.55 ± 0.02 μM (216 ± 8 μg; high dose; n = 6), and 4.55 ± 0.1 μM (1774 ± 39 μg; extreme dose; n = 5) of D-24851 were randomly implanted in New Zealand rabbit right iliac arteries and the animals were sacrificed after 28 days for histomorphometric analysis. For the assessment of endothelial regrowth in 90 days, 12 rabbits were subjected to PLGA-coated (n = 3), low-dose (n = 3), high-dose (n = 3), and extreme-dose (n = 3) stent implantation. In vitro studies revealed that D-24851 exerts its growth inhibitory effects via inhibition of proliferation and induction of apoptosis without increasing the expression of heat shock protein-70, a cytoprotective and antiapoptotic protein. Treatment with low-dose D-24851 stents was associated with a significant reduction in neointimal area and percentage stenosis only compared with bare metal stents (38% [P = 0.029] and 35% [P = 0.003] reduction, respectively). Suboptimal healing, however, was observed in all groups of D-24851-loaded stents in 90 days in comparison with PLGA-coated stents. We conclude that low-dose D-24851-eluting polymer-coated stents significantly inhibit neointimal hyperplasia at 28 days through inhibition of proliferation and enhancement of apoptosis. In view of the suboptimal re-endothelialization, longer-term studies are needed in order to establish whether the inhibition of intimal growth is maintained.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00270-007-9027-4/MediaObjects/270_2007_9027_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00270-007-9027-4/MediaObjects/270_2007_9027_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00270-007-9027-4/MediaObjects/270_2007_9027_Fig3_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00270-007-9027-4/MediaObjects/270_2007_9027_Fig4_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00270-007-9027-4/MediaObjects/270_2007_9027_Fig5_HTML.gif)
Similar content being viewed by others
References
Farb A, Sangiorgi G, Carter AJ, et al. (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99:44–52
Bennet MR (2003) In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 89:218–224
Drachman DE, Edelman ER, Seifert P, et al. (2000) Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 36:2325–2332
Suzuki T, Kopia G, Hayashi S, et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188–1193
Hou D, Narciso H, Kamdar K, et al. (2005) Stent-based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model. Cardiovasc Intervent Radiol 28(1):60–65
Morice MC, Serruys PW, Sousa JE, et al. (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780
Grube E, Silber S, Hauptmann KE, et al. (2003) TAXUS-1: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38–42
Mosser DD, Caron AW, Bourget L, et al. (1997) Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 17:5317–5327
Kwak HJ, Jun CD, Pae HO, et al. (1998) The role of inducible 70-kDa heat shock protein in cell cycle control, differentiation, and apoptotic cell death of the human myeloid leukemic HL-60 cells. Cell Immunol 187:1–12
Lee WC, Lin KY, Chen KD, et al. (1992) Induction of HSP70 is associated with vincristine resistance in heat-shocked 9L rat brain tumor cells. Br J Cancer 66:653–659
Ito H, Shimojo T, Fujisaki H, et al. (1999) Thermal pre-conditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Life Sci 64:755–761
Bacher G, Nickel B, Emig P, et al. (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 61:392–399
Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition. Circ Res 86:879–884
Raman VK, Edelman ER (1998) Coated stents: local pharmacology. Semin Intervent Cardiol 3:133–137
Cao W, Mohacsi P, Shorthouse R, et al. (1995) Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59:390–395
Morris RE (1992) Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 6:39–87
Seker H, Bertram B, Burkle A, et al. (2000) Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br J Cancer 82:629–634
Schwartz RS, Huber KC, Murphy JG, et al. (1992) Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19:267–274
Kornowski R, Hong MK, Tio FO, et al. (1998) In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224 –230
Guzman LA, Labhasetwar V, Song C, et al. (1996) Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94:1441–1448
Whitley D, Goldberg SP, Jordan WD (1999) Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 29:748–751
Helmbrecht K, Zeise E, Rensing L (2000) Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33:341–365
Kirby LB, Mondy JS, Brophy CM (1999) Balloon angioplasty induces heat shock protein 70 in human blood vessels. Ann Vasc Surg 13:475–479
Gehrmann M, Pfister K, Hutzler P, et al. (2002) Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. Biol Chem 383:1715–1725
Ito H, Kanzawa T, Kondo S, et al. (2005) Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation. Int J Oncol 26(3):589–596
Scott S, O’Sullivan M, Hafizi S, et al. (2002) Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: implications for brachytherapy and drug treatment for restenosis. Circ Res 90(4):398–404
Heldman AW, Cheng L, Jenkins GM, et al. (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289–2295
Farb A, Heller PF, Shroff S, et al. (2001) Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104:473–447
Acknowledgments
This study was funded by the Michaelideion Cardiac Center and the Medispes SW AG, Greece.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lysitsas, D.N., Katsouras, C.S., Papakostas, J.C. et al. Antirestenotic Effects of a Novel Polymer-Coated D-24851 Eluting Stent. Experimental Data in a Rabbit Iliac Artery Model. Cardiovasc Intervent Radiol 30, 1192–1200 (2007). https://doi.org/10.1007/s00270-007-9027-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-007-9027-4